BRIDGEWATER, N.J., Feb. 19, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare
diseases, today announced that Will Lewis, Chairman and Chief
Executive Officer of Insmed, will present at the 9th
Annual SVB Leerink Global Healthcare Conference in New
York, NY on Wednesday,
February 26, 2020 at 11:30 a.m. ET.
The fireside chat will be webcast live and can be accessed by
visiting the investor relations section of the company's website
at www.insmed.com. The webcast will be archived for a period
of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is
ARIKAYCE® (amikacin liposome inhalation
suspension), which is approved in the United States for
the treatment of Mycobacterium avium complex (MAC)
lung disease as part of a combination antibacterial drug regimen
for adult patients with limited or no alternative treatment
options. MAC lung disease is a rare and often chronic infection
that can cause irreversible lung damage and can be fatal. Insmed's
earlier-stage clinical pipeline includes INS1007, a novel oral
reversible inhibitor of dipeptidyl peptidase 1 with therapeutic
potential in non-cystic fibrosis bronchiectasis and other
inflammatory diseases, and INS1009, an inhaled formulation of a
treprostinil prodrug that may offer a differentiated product
profile for rare pulmonary disorders, including pulmonary arterial
hypertension. For more information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 487-7468
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-301005461.html
SOURCE Insmed Incorporated